Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option
- 15 September 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (18) , 6222-6230
- https://doi.org/10.1158/1078-0432.ccr-04-0823
Abstract
Purpose: In the brain, tumors may grow without inducing angiogenesis, via co-option of the dense pre-existent capillary bed. The purpose of this study was to investigate how this phenomenon influences the outcome of antiangiogenic therapy. Experimental Design: Mice carrying brain metastases of the human, highly angiogenic melanoma cell line Mel57-VEGF-A were either or not treated with different dosages of ZD6474, a vascular endothelial growth factor (VEGF) receptor 2 tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor. Effect of treatment was evaluated using contrast-enhanced magnetic resonance imaging (CE- MRI) and (immuno)morphologic analysis. Results: Placebo-treated Mel57-VEGF-A brain metastases evoked an angiogenic response and were highlighted in CE-MRI. After treatment with ZD6474 (100 mg/kg), CE-MRI failed to detect tumors in either prevention or therapeutic treatment regimens. However, (immuno)histologic analysis revealed the presence of numerous, small, nonangiogenic lesions. Treatment with 25 mg/kg ZD6474 also resulted in efficient blockade of vessel formation, but it did not fully inhibit vascular leakage, thereby still allowing visualization in CE-MRI scans. Conclusions: Our data show that, although angiogenesis can be effectively blocked by ZD6474, in vessel-dense organs this may result in sustained tumor progression via co-option, rather than in tumor dormancy. Importantly, blocking VEGF-A may result in undetectability of tumors in CE-MRI scans, leading to erroneous conclusions about therapeutic efficacy during magnetic resonance imaging follow-up. The maintenance of VEGF-A-induced vessel leakage in the absence of neovascularization at lower ZD6474 doses may be exploited to improve delivery of chemotherapeutic agents in combined treatment regimens of antiangiogenic and chemotherapeutic compounds.Keywords
This publication has 26 references indexed in Scilit:
- Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrinCancer Cell, 2003
- Vascular endothelial growth factor‐A determines detectability of experimental melanoma brain metastasis in GD‐DTPA‐enhanced MRI.International Journal of Cancer, 2003
- Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution studyInternational Journal of Cancer, 2002
- Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1Journal of Biological Chemistry, 2002
- Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1Laboratory Investigation, 2002
- Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein SynthesisScience, 2002
- Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasiaThe Journal of Pathology, 2001
- The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin ?v?3 expressionInternational Journal of Cancer, 2001
- Vascular Endothelial Growth Factor Stimulates Proliferation but Not Migration or Invasiveness in Human Extravillous Trophoblast1Biology of Reproduction, 1998
- Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4Oncogene, 1997